Cancer Research and Treatment

Original Articles

General

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy: Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim; Cancer Res Treat. 2023;55(4):1096-1103. Published online April 7, 2023; DOI: https://doi.org/10.4143/crt.2022.1565

Abstract PDF Supplementary Material PubReader ePub

Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by

Evaluation of self-assembling properties of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
Nano-Structures & Nano-Objects.2024; 40: 101375. CrossRef

3,751 View
220 Download
1 Crossref

Breast cancer

Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors: Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho; Cancer Res Treat. 2022;54(4):1065-1073. Published online December 8, 2021; DOI: https://doi.org/10.4143/crt.2021.835

Abstract PDF Supplementary Material PubReader ePub

Purpose
Fear of cancer recurrence (FCR) is a common psychological issue in breast cancer (BC) survivors during early survivorship but whether the same is true among long-term survivors has yet to be empirically evaluated. This study investigated FCR level, its associated factors, and impact on quality of life (QoL) in long-term BC survivors.
Materials and Methods
Participants included women diagnosed with BC between 2004 and 2010 at two tertiary hospitals. Survey was conducted in 2020. The study measured FCR with the Fear of Cancer Recurrence Inventory and other patient-reported outcomes, including depression and cancer-related QoL. Logistic regression was used to identify factors associated with FCR, and structural equation modeling was conducted to explore the impact of FCR on other outcomes.
Results
Of 333 participants, the mean age at diagnosis was 45.5, and 46% experienced FCR. Age at diagnosis ≤ 45 (adjusted odds ratio [aOR], 2.64; 95% confidence interval [CI], 1.51 to 4.60), shorter time since diagnosis (aOR, 1.75, 95% CI, 1.08 to 2.89), and having a history of recurrence (aOR, 2.56; 95% CI, 1.16 to 5.65) was associated with more FCR. FCR was significantly associated with an increased risk of depression (β=0.471, p < 0.001) and negatively impacted emotional functioning (β=–0.531, p < 0.001). In addition, a higher FCR level may impair overall health-related QoL in long-term BC survivors (β=–0.108, p=0.021).
Conclusion
Ten years after diagnosis, long-term BC survivors still experienced a high level of FCR. Further, the negative impact of FCR on QoL and increased depression risk require an FCR screening and appropriate interventions to enhance long-term BC survivors' QoL.

Citations

Citations to this article as recorded by

Health-related quality of life in long-term early-stage breast cancer survivors compared to general population in Korea
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoonjung Chang, Hyunsoon Cho
Journal of Cancer Survivorship.2025; 19(2): 487. CrossRef
CANCER. Is this Forever? Examining the Relationship Between Event Centrality and Fear of Cancer Recurrence from a Cognitive-Behavioral Standpoint
Diana Todea, Andreea Luca, Ioana R. Podina
Journal of Rational-Emotive & Cognitive-Behavior Therapy.2025;[Epub] CrossRef
Fear of the Cancer Coming Back: A Metasynthesis of Fear of Recurrence in Breast Cancer
Kai‐Yue Wang, Hui Li, Nan Qin
Public Health Nursing.2025; 42(1): 457. CrossRef
Social support, fear of cancer recurrence and sleep quality in breast cancer: A moderated network analysis
Yingting Jiang, Xinyu Wu, Hongman Li, Ying Xiong, M. Tish Knobf, Zengjie Ye
European Journal of Oncology Nursing.2025; 74: 102799. CrossRef
Dyadic effects of illness perception and maladaptive cognitive-emotional regulation strategies on the fear of cancer recurrence in breast cancer patients and spouses: an actor-partner interdependence mediation model
Hui Ren, Tianye Yang, Songli Mei, Zhu Zhu, Jianjun Shi, Lingling Tong, Jia Yang, Yabin Sun
BMC Psychiatry.2025;[Epub] CrossRef
Validating the Black Identity, Hair Product Use, and Breast Cancer Scale (BHBS) Among Black Breast Cancer Survivors
Dede K. Teteh-Brooks, Marissa Ericson, Traci N. Bethea, Lenna Dawkins-Moultin, Nicole Sarkaria, Jared Bailey, Adana A. M. Llanos, Susanne Montgomery
International Journal of Environmental Research and Public Health.2025; 22(2): 174. CrossRef
The Lived Experience of Suffering by Nigerian Female Breast Cancer Survivors: A Phenomenological Perspective
Chinomso Ugochukwu Nwozichi, Margaret Olutosin Ojewale, Omolabake Salako, Deliverance Brotobor, Elizabeth Olaogun
Journal of Patient Experience.2025;[Epub] CrossRef
Examining the Sequential Relationships Between Voice Changes, Symptom Experiences, Fear of Cancer Recurrence, and Voice-Related Quality of Life in Patients With Thyroid Cancer
Myung Kyung Lee, Jihyun Oh
Cancer Nursing.2025;[Epub] CrossRef
Cancer Recurrence Fear and Return to Work in Breast Cancer Survivors:The Mediating Effects of Health Literacy
Xiaoli Zhu, Juanjuan Lei, Rong Chen, Zhu Chen, Zhengchong Xiong, Lin Yang, Mengxiao Jiang, Huiting Zhang
Journal of Multidisciplinary Healthcare.2025; Volume 18: 1031. CrossRef
Satisfaction with and perceived benefits of needs-assessment related to rehabilitation after chemotherapy among patients with breast cancer
Marta Kramer Mikkelsen, Helle Elisabeth Jensen, Guri Spiegelhauer, Kirsten Amdi, Kasper Madsen, Kirstine Steen Nybom, Rikke Balschmidt Holm-Petersen, Dorte Nielsen
Disability and Rehabilitation.2024; 46(12): 2548. CrossRef
Fear of recurrence in postoperative lung cancer patients: Trajectories, influencing factors and impacts on quality of life
Xiaoyan Yang, Yonglin Li, Jialing Lin, Jianqing Zheng, Huimin Xiao, Weiti Chen, Feifei Huang
Journal of Clinical Nursing.2024; 33(4): 1409. CrossRef
Unmet care needs of women who have undergone breast cancer surgery: A scoping review
Qiaohong Ke, Fiona Timmins, Eileen Furlong, Diarmuid Stokes
Journal of Advanced Nursing.2024; 80(5): 1732. CrossRef
Dyadic association between mindfulness, family avoidance of communication about cancer and fear of cancer recurrence among breast cancer couples: A cross-sectional study
Xiangyu Zhao, Yunxue Zhang, Rui Qin, Guopeng Li, Xudong He, Xiaona Shen, Ping Li
European Journal of Oncology Nursing.2024; 68: 102491. CrossRef
Prevalence and Factors Contributing to Fear of Recurrence in Breast Cancer Patients and Their Partners: A Cross-Sectional Study
Ling Tong, Yuan Wang, Dewu Xu, Yibo Wu, Ling Chen
International Journal of Women's Health.2024; Volume 16: 229. CrossRef
Fear of Cancer Progression: A Comparison between the Fear of Progression Questionnaire (FoP-Q-12) and the Concerns about Recurrence Questionnaire (CARQ-4)
Andreas Hinz, Thomas Schulte, Anja Mehnert-Theuerkauf, Diana Richter, Annekathrin Sender, Hannah Brock, Michael Friedrich, Susanne Briest
Healthcare.2024; 12(4): 435. CrossRef
Factors affecting the fear of recurrence in Breast cancer patients
Dinara Kussainova, Anar Tursynbekova, Gulshara Aimbetova, Fatima Bagiyarova, Dilyara Kaidarova
Research Journal of Pharmacy and Technology.2024; : 314. CrossRef
Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Jacob Hampton, Ahmad Alam, Nicholas Zdenkowski, Christopher Rowe, Elizabeth Fradgley, Christine J. O'Neill
Thyroid®.2024; 34(5): 541. CrossRef
Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens
Robert W. Mutter, Cynthia Chauhan, Matthew P. Goetz, Jean L. Wright
Journal of Clinical Oncology.2024; 42(18): 2121. CrossRef
The impact of fear of cancer recurrence on the quality of life of breast cancer patients: A longitudinal study of the mediation effect of cortisol and hope
Meidi Xiong, Yuping Cheng, Ying Luo, Chao Fang, Hongmei Yao, Qianqian Liu, Fang Lu, Xuan Li, Ziying Bie, Jinbing Bai, Chunhua Zhang
European Journal of Oncology Nursing.2024; 70: 102600. CrossRef
Psychosocial factors associated with quality of life in cancer survivors: umbrella review
Viktorya Voskanyan, Chiara Marzorati, Diana Sala, Roberto Grasso, Ricardo Pietrobon, Iris van der Heide, Merel Engelaar, Nanne Bos, Augusto Caraceni, Norbert Couspel, Montse Ferrer, Mogens Groenvold, Stein Kaasa, Claudio Lombardo, Aude Sirven, Hugo Vachon
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines
Mitchell J. Elliott, Sherry Shen, Diana L. Lam, Thelma Brown, Marissa B. Lawson, Neil M. Iyengar, David W. Cescon
American Society of Clinical Oncology Educational Book.2024;[Epub] CrossRef
Dyadic effects of financial toxicity and social support on the fear of cancer recurrence in breast cancer patients and caregivers: an actor–partner interdependence mediation model
Hongyan Li, Yabin Sun, Tianye Yang, Xin Yin, Zhu Zhu, Jianjun Shi, Lingling Tong, Jia Yang, Hui Ren
BMC Nursing.2024;[Epub] CrossRef
Understanding Reasons for Cancer Disparities in Italy: A Qualitative Study of Barriers and Needs of Cancer Patients and Healthcare Providers
Giulia Ferraris, Veronica Coppini, Maria Vittoria Ferrari, Dario Monzani, Roberto Grasso, Gabriella Pravettoni
Cancer Control.2024;[Epub] CrossRef
Latent profile analysis and related factors for fear of cancer recurrence among Chinese breast cancer patients in rehabilitation
Yinjie Bai, Jing Zhang, Yujing Sun, Yingying Wang, Huangfei Xu
European Journal of Oncology Nursing.2024; 71: 102651. CrossRef
Infographics on signs and symptoms of metastatic (secondary) breast cancer can empower women with a breast cancer diagnosis
Nazanin Derakshan, Joanne Taylor, Bethany Chapman
Frontiers in Psychology.2024;[Epub] CrossRef
Virtual body and emotions: A pilot study on the use of virtual reality for the management of unpleasant sensations after cancer
Valeria Sebri, Ilaria Durosini, Milija Strika, Silvia Francesca Maria Pizzoli, Ketti Mazzocco, Gabriella Pravettoni
Counselling and Psychotherapy Research.2024; 24(4): 1632. CrossRef
Correlation between symptom experience and fear of cancer recurrence in postoperative breast cancer patients undergoing chemotherapy in China: A cross-sectional study
Manxia Han, Huaying Chen, Jialing Li, Xuemei Zheng, Xue Zhang, Lin Tao, Xiaoxia Zhang, Xianqiong Feng, Tim Luckett
PLOS ONE.2024; 19(9): e0308907. CrossRef
Addressing the Arguments Against Omitting Radiotherapy After Breast-Conserving Surgery for Early Luminal Breast Cancers
A. Maghous, I. Lalya, E. Marnouche, M. Hommadi, M. Belemlih, K. Andaloussi Saghir, M. Elmarjany, K. Hadadi, H. Sifat
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Fear of Cancer Recurrence and Unmet Needs in Triple Negative Breast Cancer Survivors
Ka Ryeong Bae, So Hee Kim
Asian Oncology Nursing.2024; 24(3): 125. CrossRef
Facilitating and Inhibiting Factors in Deciding to Start Retreatment in Survivors of Breast Cancer Recurrence
Mahsa Matbouei, Majid Samsami, Mohsen Soleimani
International Journal of Cancer Management.2023;[Epub] CrossRef
Adjuvant breast radiotherapy in patients aged 65 and over: Not a binary decision
D. Azria, C. Bourgier, C. Lemanski
Cancer/Radiothérapie.2023; 27(3): 181. CrossRef
Effects of CALM intervention on neutrophil-to-lymphocyte ratio (NLR), fear of cancer recurrence and quality of life in patients with lung cancer
Jie Zhao, Menglian Wang, Runze Huang, Jian Xu, Chen Gan, Sheng Yu, Lingxue Tang, Senbang Yao, Wen Li, Huaidong Cheng
Supportive Care in Cancer.2023;[Epub] CrossRef
Factors associated with health-related quality of life in a cohort of cancer survivors in New Jersey
Sharon Manne, Katie Devine, Shawna Hudson, Deborah Kashy, Denalee O’Malley, Lisa E. Paddock, Elisa V. Bandera, Adana A. M. Llanos, Angela Fong, Neetu Singh, Sara Frederick, Andrew M. Evens
BMC Cancer.2023;[Epub] CrossRef
Fear of cancer recurrence in South Korean survivors of breast cancer who have received adjuvant endocrine therapy: a cross-sectional study
Seul Ki Park, Yul Ha Min
Frontiers in Psychology.2023;[Epub] CrossRef
Altered regional homogeneity and homotopic connectivity in Chinese breast cancer survivors with fear of cancer recurrence: A resting-state fMRI study
Li Peng, Xiaofei Hu, Chen Xu, Yuanyuan Xu, Han Lai, Ying Yang, Ju Liu, Yuan Xue, Min Li
Journal of Psychosomatic Research.2023; 173: 111454. CrossRef
Protective Factors against Fear of Cancer Recurrence in Breast Cancer Patients: A Latent Growth Model
Gabriella Bentley, Osnat Zamir, Rawan Dahabre, Shlomit Perry, Evangelos C. Karademas, Paula Poikonen-Saksela, Ketti Mazzocco, Berta Sousa, Ruth Pat-Horenczyk
Cancers.2023; 15(18): 4590. CrossRef
Cost-effectiveness versus treatment effectiveness: A radiation oncologist's dilemma in low-income and middle-income countries (LMIC)
Priya Iyer
The Lancet Regional Health - Southeast Asia.2022; 4: 100061. CrossRef

8,172 View
245 Download
36 Web of Science
37 Crossref

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study: Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim; Cancer Res Treat. 2018;50(2):488-494. Published online May 22, 2017; DOI: https://doi.org/10.4143/crt.2016.584

Abstract PDF Supplementary Material PubReader ePub

Purpose
The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Materials and Methods
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
Results
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
Conclusion
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.

Citations

Citations to this article as recorded by

Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran
Journal of Oncology Pharmacy Practice.2025; 31(1): 128. CrossRef
Liver metastasis from a chromophobe renal cell carcinoma 18 years after initial diagnosis: a case report
Alexandra Ökrösi, Lothar Ponhold, Simon Turba, Melitta Kitzwögerer, Gertraud Heinz
Journal of Medical Case Reports.2025;[Epub] CrossRef
Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andra
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
Albert Jang, Charbel S. Hobeika, Shilpa Gupta
Kidney Cancer.2024; 8(1): 61. CrossRef
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, G
Journal of Chemotherapy.2024; : 1. CrossRef
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective
Gaetano Pezzicoli, Vittoria Musci, Federica Ciciriello, Francesco Salonne, Paola Cafforio, Nicoletta Lionetti, Anna Ragno, Mimma Rizzo
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
Frontiers in Oncology.2024;[Epub] CrossRef
Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma
Floriane Izarn, Benoît Allignet, Romane Gille, Helen Boyle, Eve-Marie Neidhardt, Sylvie Négrier, Aude Fléchon
Clinical Genitourinary Cancer.2023; 21(2): e35. CrossRef
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba
Clinical and Translational Oncology.2023; 25(9): 2732. CrossRef
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğl
Urologia Internationalis.2023; 107(6): 595. CrossRef
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Oh
Cancer Medicine.2023; 12(22): 20677. CrossRef
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Pay
Journal of the National Comprehensive Cancer Network.2022; 20(1): 71. CrossRef
Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata
Kidney Cancer.2022; 6(1): 53. CrossRef
Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough
International Journal of Translational Medicine.2022; 2(4): 555. CrossRef
Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds
Panagiotis Zoumpourlis, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel
Clinical Genitourinary Cancer.2021; 19(2): 103. CrossRef
Comprehensive review of chromophobe renal cell carcinoma
Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush
Critical Reviews in Oncology/Hematology.2021; 160: 103287. CrossRef
A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
Chelsea K. Osterman, Tracy L. Rose
Kidney Cancer.2020; 4(1): 15. CrossRef
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida
Journal of Medical Case Reports.2020;[Epub] CrossRef
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Management of Metastatic Renal Cell Carcinoma with Variant Histologies
Ronan Flippot, Vijay Damarla, Bradley A. McGregor
Urologic Clinics of North America.2020; 47(3): 319. CrossRef
Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors
Silvia Salerno, Elisabetta Barresi, Aída Nelly García-Argáez, Sabrina Taliani, Francesca Simorini, Giorgio Amendola, Stefano Tomassi, Sandro Cosconati, Ettore Novellino, Federico Da Settimo, Anna Maria Marini, Lisa Dalla Via
ACS Medicinal Chemistry Letters.2019; 10(4): 457. CrossRef
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tri
The Lancet Oncology.2019; 20(4): 581. CrossRef
Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas
Keiichi Ito
International Journal of Urology.2019; 26(9): 868. CrossRef
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee
BMC Urology.2019;[Epub] CrossRef
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
Gregory T. Sneed, Sukdong Lee, Jamie N. Brown, Julia M. Hammond
Clinical Genitourinary Cancer.2019; 17(6): 419. CrossRef
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
Inkeun Park, Se Hoon Lee, Jae Lyun Lee
Clinical Genitourinary Cancer.2018; 16(5): e997. CrossRef
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan
Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayaka
Clinical Genitourinary Cancer.2018; 16(6): e1201. CrossRef

11,047 View
494 Download
38 Web of Science
30 Crossref

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08: Ki Hyang Kim, Joo Hoon Kim, Ji Young Lee, Hyo Song Kim, Su Jin Heo, Ji Hyung Kim, Ho Young Kim, Sun Young Rha; Cancer Res Treat. 2016;48(4):1286-1292. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2016.018

Abstract PDF PubReader ePub

Purpose
We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment.
Results
Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

Citations

Citations to this article as recorded by

Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis
Manuel Eros Rodríguez-Fuentes, Mario Pérez-Sayáns, Carmen Martín Carreras-Presas, Xabier Marichalar-Mendia, Leticia Bagán-Debón, Rafael López-López
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(3): 385. CrossRef
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka
Cancer Chemotherapy and Pharmacology.2021; 87(6): 723. CrossRef
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
Cristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, Giuseppe Procopio, Ugo de Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Francesco Atzori, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Guida, Annalisa B
Clinical Genitourinary Cancer.2019; 17(1): e150. CrossRef
Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials
Ravi K. Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju
Oncology Reviews.2019;[Epub] CrossRef

10,472 View
144 Download
3 Web of Science
4 Crossref

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma: Ho Young Kim, Ju-Seok Kim, Dae Ro Choi, Hyeong Su Kim, Jung Hye Kwon, Geun-Doo Jang, Jung Han Kim, Joo Young Jung, Hun Ho Song, Young Kyung Lee, Soo Kee Min, Hee Sung Hwang, Hwa Jung Kim, Dae Young Zang, Hyo Jung Kim; Cancer Res Treat. 2015;47(3):458-464. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.091

Abstract PDF PubReader ePub

Purpose
Bone marrow biopsy is a standard method for the evaluation of bone marrow infiltration by lymphoma; however, it is an invasive and painful procedure. Fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) is a noninvasive imaging technique with the potential to detect bone marrow involvement by lymphoma. Materials and Methods We retrospectively reviewed medical records of lymphoma patients. All patients were examined by FDG PET-CT and iliac crest bone marrow biopsy for initial staging work-up. Results The study population comprised 94 patients (median age, 60 years; 56 males) with Hodgkin’s lymphoma (n=8) or non-Hodgkin’s lymphoma (n=86). Maximum standardized uptake values on the iliac crest of patients with lymphoma infiltrated bone marrow were significantly higher than those of patients with intact bone marrow (2.2±1.2 g/mL vs. 1.3±0.4 g/mL; p=0.001). The calculated values for FDG PET-CT during evaluation of bone marrow involvement were as follows: sensitivity 50%, specificity 96%, positive predictive value 80%, negative predictive value 85%, and positive likelihood ratio (LR+) 11.7. The value of LR+ was 16.0 in patients with aggressive subtypes of non-Hodgkin’s lymphoma (NHL). Conclusion FDG PET-CT could not replace bone marrow biopsy due to the low sensitivity of FDG PET-CT for detection of bone marrow infiltration in lymphoma patients. Conversely, FDG PET-CT had high specificity and LR+; therefore, it could be a useful tool for image-guided biopsy for lymphoma staging, especially for aggressive subtypes of NHL. In addition, unilateral bone marrow biopsy could be substituted for bilateral bone marrow biopsy in lymphoma patients with increased FDG uptake on any iliac crest.

Citations

Citations to this article as recorded by

FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review
Jawaher Almaimani, Charalampos Tsoumpas, Richard Feltbower, Irene Polycarpou
Applied Sciences.2022; 12(2): 540. CrossRef
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review
Jung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kim
Cancer Chemotherapy and Pharmacology.2017; 80(4): 729. CrossRef
Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
Seon Jeong Min, Hyun Joo Jang, Jung Han Kim
Oncotarget.2016; 7(19): 27848. CrossRef

12,972 View
132 Download
5 Web of Science
3 Crossref

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee: Kyung A Kwon, Sung Yong Oh, Ho Young Kim, Hyo Song Kim, Ha Young Lee, Tae Min Kim, Ho Yeong Lim, Na-Ri Lee, Hyo Jin Lee, Sook Hee Hong, Sun Young Rha; Cancer Res Treat. 2014;46(2):141-147. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.141

Abstract PDF PubReader ePub

Purpose

Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.

Materials and Methods

From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.

Results

Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.

Conclusion

CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

Citations

Citations to this article as recorded by

Collecting Duct Carcinoma: Characteristics and Survival Outcomes From UroCCR Database (CDCSurv UroCCR n°141)
Louis-Pacôme Le Mével, Jean-Christophe Bernhard, Mokrane Yacoub, Thibaut Waeckel, Céline Bazille, Cécile Champy, Maria Mamodaly, Karim Bensalah, Nathalie Rioux-Leclercq, Constance Michel, Ilhem Hergli, Louis Surlemont, Julie Leclerc, Morgan Roupret, Franc
Clinical Genitourinary Cancer.2025; 23(2): 102305. CrossRef
Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports
Sang Bin Bae, Seong Kuk Yoon, Seo-hee Rha
Journal of the Korean Society of Radiology.2024; 85(1): 222. CrossRef
A curious case: Concurrent collecting duct renal cell carcinoma and upper tract urothelial carcinoma
Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
Urology Case Reports.2024; 54: 102698. CrossRef
Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning
Tianyi Shi, Xiucai Ye, Dong Huang, Tetsuya Sakurai
Methods.2024; 231: 144. CrossRef
Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
Zoé Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, François Audenet, Yann-Alexandre Vano, Stéphane Oudard, Constance Thibault
Bulletin du Cancer.2023; 110(4): 450. CrossRef
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu
Cancers.2022; 14(7): 1678. CrossRef
Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists
Benjamin Laguna, Antonio C. Westphalen, C. T. Guimarães, Zhen Whang, Jeff Simko, Ronald Zagoria
Abdominal Radiology.2019; 44(4): 1430. CrossRef
Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors
A. Pinto, M. Garrido, C. Aguado, T. Alonso, P. Gajate, C. Maximiano, I. García-Carbonero, A. Martín, I. Gallegos, J.A. Arranz, J. Puente, E. Grande
Kidney Cancer.2019; 3(3): 177. CrossRef
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal
Kidney Cancer.2017; 1(2): 99. CrossRef
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
Gabriel G. Malouf, Eva Compérat, Hui Yao, Roger Mouawad, Veronique Lindner, Nathalie Rioux-leclercq, Virginie Verkarre, Xavier Leroy, Linda Dainese, Marion Classe, Jean-Luc Descotes, Philippe Barthelemy, Mokrane Yacoub, Morgan Rouprêt, Jean-Christophe Ber
Scientific Reports.2016;[Epub] CrossRef
Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases
ZHENSHAN SHI, QIAN ZHUANG, RUIXIONG YOU, YUEMING LI, JIAN LI, DAIRONG CAO
Oncology Letters.2016; 11(1): 261. CrossRef
Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation
Jianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Qiang Hu, Kiersten Marie Miles, Jeffrey M. Conroy, Sean T. Glenn, Manuela Costantini, Cristina Magi-Galluzzi, Sabina Signoretti, Toni Choueiri, Michele Gallucci, Steno Se
Oncotarget.2016; 7(21): 29901. CrossRef

12,147 View
73 Download
16 Web of Science
12 Crossref

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naive Cancer Patients: Geundoo Jang, Hun Ho Song, Keon Uk Park, Hyeong Su Kim, Dae Ro Choi, Jung Hye Kwon, Ho Young Kim, Boram Han, Jung Han Kim, Joo Young Jung, Hyo Jung Kim, Dae Young Zang; Cancer Res Treat. 2013;45(3):172-177. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.172

Abstract PDF PubReader ePub

PURPOSE
Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). However, it is not known whether ramosetron is suitable for administration in combination with aprepitant. Therefore, we conducted a multicenter, open-label, prospective, phase II study in order to assess the efficacy and tolerability of combination therapy with ramosetron, aprepitant, and dexamethasone (RAD) for prevention of cisplatin-based CINV in chemotherapy-naive patients with solid cancers.
MATERIALS AND METHODS
Forty-one patients with various solid cancers (31 male and 10 female; median age, 59 years) who received treatment with highly emetogenic chemotherapy (median cisplatin dose, 70 mg/m2; range 50 to 75 mg/m2) were enrolled in this study. Oral aprepitant (125 mg on day 1; 80 mg on days 2 and 3), intravenous ramosetron (0.6 mg on day 1), and oral dexamethasone (12 mg on day 1; 8 mg on days 2-4) were administered for prevention of CINV.
RESULTS
The complete response (no emesisand retching and no rescue medication) rate was 94.9% in the acute period (24 hours post-chemotherapy), 92.3% in the delayed period (24-120 hours post-chemotherapy), and 92.3% in the overall period (0-120 hours). The absolute complete response (complete response plus no nausea) rate was 74.4% in the acute period, 51.3% in the delayed period, and 46.2% in the overall period. There were no grade 3 or 4 toxicities related to these antiemetic combinations.
CONCLUSION
RAD regimen is a safe and effective antiemetic treatment for prevention of CINV in patients receiving highly emetogenic chemotherapy.

Citations

Citations to this article as recorded by

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21
Hyo Jung Kim, Sang Won Shin, Eun-Kee Song, Na-Ri Lee, Jun Suk Kim, Jin Seok Ahn, Hwan-Jung Yun, Yo-Han Cho, Keon Uk Park, Si-Young Kim, Joung Soon Jang, Sang-We Kim, Hyun Woo Lee, Se Ryeon Lee, Yang Soo Kim, Soon Nam Lee, Yoon Ho Ko, Hwa Jung Kim, Jin-Hyo
The Oncologist.2015; 20(12): 1440. CrossRef
Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration
Hannah Kenward, Ludovic Pelligand, Jonathan Elliott
Experimental Brain Research.2014; 232(8): 2685. CrossRef
Anticipatory nausea in animal models: a review of potential novel therapeutic treatments
Erin M. Rock, Cheryl L. Limebeer, Linda A. Parker
Experimental Brain Research.2014; 232(8): 2511. CrossRef

11,942 View
72 Download
3 Crossref

First
Prev
Page of 1
Next
Last

Search